Gland Pharma Ltd. (GLAND) Stock Forecast & Price Target

Compare

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

GLAND Analyst Ratings

Moderate Buy

2 Buy

0 Hold

0 Sell

Based on 2 analysts giving stock ratings to

Gland

Pharma Ltd.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

GLAND Stock 12 Month Forecast

Average Price Target

₹2,222.50

▲(29.67% Upside)

Based on 2 Wall Street analysts offering 12 month price targets for Gland Pharma Ltd. in the last 3 months. The average price target is ₹2,222.50 with a high forecast of ₹2,275.00 and a low forecast of ₹2,170.00. The average price target represents a 29.67% change from the last price of ₹1,713.95.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1511":"₹1,511","2276":"₹2,276","1702.25":"₹1,702.3","1893.5":"₹1,893.5","2084.75":"₹2,084.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2275,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹2.27K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2222.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹2.22K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2170,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹2.17K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1511,1702.25,1893.5,2084.75,2276],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Sep<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1715.25,1758.3076923076924,1801.3653846153845,1844.423076923077,1887.4807692307693,1930.5384615384614,1973.5961538461538,2016.6538461538462,2059.7115384615386,2102.769230769231,2145.826923076923,2188.8846153846152,2231.9423076923076,{"y":2275,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1715.25,1754.2692307692307,1793.2884615384614,1832.3076923076924,1871.326923076923,1910.3461538461538,1949.3653846153845,1988.3846153846152,2027.4038461538462,2066.423076923077,2105.4423076923076,2144.4615384615386,2183.480769230769,{"y":2222.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1715.25,1750.2307692307693,1785.2115384615386,1820.1923076923076,1855.173076923077,1890.1538461538462,1925.1346153846155,1960.1153846153848,1995.0961538461538,2030.076923076923,2065.0576923076924,2100.0384615384614,2135.019230769231,{"y":2170,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1635.61,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1762.98,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1762.98,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1793.1,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1512.31,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1538.07,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1540.7,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1859.38,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1960.93,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1868.8,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1980.55,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1726.2,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1715.25,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target₹2,275

Average Price Target₹2,223

Lowest Price Target₹2,170

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Abdulkader Puranwala

ICICI Securities

₹2,275

Buy

32.73%

Upside

Reiterated

01/29/26

ICICI Securities Reaffirms Their Buy Rating on Gland Pharma Ltd. (GLAND)

Unknown Analyst

Motilal Oswal

Not Ranked

Motilal Oswal

₹2,050

Buy

19.61%

Upside

Reiterated

01/28/26

Motilal Oswal Remains a Buy on Gland Pharma Ltd. (GLAND)

Alankar Garude

Kotak Mahindra

₹1,780→₹1,800

Sell

5.02%

Upside

Reiterated

09/29/25

Kotak Mahindra Reaffirms Their Sell Rating on Gland Pharma Ltd. (GLAND)

Saion Mukherjee

Nomura

₹1,570→₹2,010

Hold

17.27%

Upside

Reiterated

08/07/25

Nomura Reaffirms Their Hold Rating on Gland Pharma Ltd. (GLAND)

Alok Dalal

Jefferies

₹1,350→₹1,970

Hold

14.94%

Upside

Upgraded

08/06/25

Jefferies upgrades Gland Pharma Ltd. (GLAND) to a Hold

Vivek Agrawal CFA

Citi

₹1,420→₹1,680

Sell

-1.98%

Downside

Reiterated

07/22/25

Citi Sticks to Their Sell Rating for Gland Pharma Ltd. (GLAND)

Shyam Srinivasan

Goldman Sachs

₹1,400→₹1,525

Sell

-11.02%

Downside

Reiterated

07/15/25

Goldman Sachs Sticks to Its Sell Rating for Gland Pharma Ltd. (GLAND)

Anshuman Gupta CFA

Investec

₹2,055→₹1,750

Buy

2.10%

Upside

Reiterated

02/04/25

Gland Pharma Ltd (GLAND:IN) PT Lowered to INR1,750 at InvestecInvestec analyst Anshuman Gupta lowered the price target on Gland Pharma Ltd (GLAND:IN) to INR1,750.00 (from INR2,055.00) while maintaining a Buy rating.

Neha Manpuria

Bank of America Securities

₹2,080→₹2,020

Buy

17.86%

Upside

Reiterated

02/04/25

Gland Pharma Ltd (GLAND:IN) PT Lowered to INR2,020 at BofA SecuritiesBofA Securities analyst Neha Manpuria lowered the price target on Gland Pharma Ltd (GLAND:IN) to INR2,020.00 (from INR2,080.00) while maintaining a Buy rating.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Abdulkader Puranwala

ICICI Securities

₹2,275

Buy

32.73%

Upside

Reiterated

01/29/26

ICICI Securities Reaffirms Their Buy Rating on Gland Pharma Ltd. (GLAND)

Unknown Analyst

Motilal Oswal

Not Ranked

Motilal Oswal

₹2,050

Buy

19.61%

Upside

Reiterated

01/28/26

Motilal Oswal Remains a Buy on Gland Pharma Ltd. (GLAND)

Alankar Garude

Kotak Mahindra

₹1,780→₹1,800

Sell

5.02%

Upside

Reiterated

09/29/25

Kotak Mahindra Reaffirms Their Sell Rating on Gland Pharma Ltd. (GLAND)

Saion Mukherjee

Nomura

₹1,570→₹2,010

Hold

17.27%

Upside

Reiterated

08/07/25

Nomura Reaffirms Their Hold Rating on Gland Pharma Ltd. (GLAND)

Alok Dalal

Jefferies

₹1,350→₹1,970

Hold

14.94%

Upside

Upgraded

08/06/25

Jefferies upgrades Gland Pharma Ltd. (GLAND) to a Hold

Vivek Agrawal CFA

Citi

₹1,420→₹1,680

Sell

-1.98%

Downside

Reiterated

07/22/25

Citi Sticks to Their Sell Rating for Gland Pharma Ltd. (GLAND)

Shyam Srinivasan

Goldman Sachs

₹1,400→₹1,525

Sell

-11.02%

Downside

Reiterated

07/15/25

Goldman Sachs Sticks to Its Sell Rating for Gland Pharma Ltd. (GLAND)

Anshuman Gupta CFA

Investec

₹2,055→₹1,750

Buy

2.10%

Upside

Reiterated

02/04/25

Neha Manpuria

Bank of America Securities

₹2,080→₹2,020

Buy

17.86%

Upside

Reiterated

02/04/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Gland Pharma Ltd.

3 Months

xxx

Success Rate

3/3 ratings generated profit

Average Return

+10.30%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +10.30% per trade.

1 Year

Alankar GarudeKotak Mahindra

Success Rate

3/3 ratings generated profit

Average Return

+11.67%

reiterated a sell rating 4 months ago

Copying Alankar Garude's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +11.67% per trade.

2 Years

xxx

Success Rate

3/3 ratings generated profit

Average Return

+10.77%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +10.77% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GLAND Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, GLAND has received 3 Buy Ratings, 15 Hold Ratings, and 0 Sell Ratings. GLAND average Analyst price target in the past 3 months is 2,222.50.

Each month's total comprises the sum of three months' worth of ratings.

GLAND Financial Forecast

GLAND Earnings Forecast

Next quarter’s earnings estimate for GLAND is ₹14.12 with a range of ₹12.30 to ₹16.40. The previous quarter’s EPS was ₹16.95. GLAND beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.25% of the time in the same period. In the last calendar year GLAND has Performed in-line its overall industry.

GLAND Sales Forecast

Next quarter’s sales forecast for GLAND is ₹16.38B with a range of ₹15.68B to ₹16.81B. The previous quarter’s sales results were ₹16.95B. GLAND beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.18% of the time in the same period. In the last calendar year GLAND has Performed in-line its overall industry.

GLAND Stock Forecast FAQ

What is IN:GLAND’s average 12-month price target, according to analysts?

Based on analyst ratings, Gland Pharma Ltd.’s 12-month average price target is 2,222.50.

What is IN:GLAND’s upside potential, based on the analysts’ average price target?

Gland Pharma Ltd. has 29.67% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Gland Pharma Ltd. a Buy, Sell or Hold?

Gland Pharma Ltd. has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.

What is Gland Pharma Ltd.’s share price target?

The average share price target for Gland Pharma Ltd. is 2,222.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ₹2,275.00 ,and the lowest forecast is ₹2,170.00. The average share price target represents 29.67% Increase from the current price of ₹1,713.95.

What do analysts say about Gland Pharma Ltd.?

Gland Pharma Ltd.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.

How can I buy shares of Gland Pharma Ltd.?

To buy shares of IN:GLAND, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Gland Pharma Ltd. (GLAND) Stock Forecast & Price Target

GLAND Analyst Ratings

GLAND Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Gland Pharma Ltd.

GLAND Analyst Recommendation Trends

GLAND Financial Forecast

GLAND Earnings Forecast

GLAND Sales Forecast

GLAND Stock Forecast FAQ

Detailed List of Analyst Forecasts